期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

索利那新治疗膀胱过度活动症4周疗效分析 被引量：12

下载PDF
导出
摘要 国际尿控协会将膀胱过度活动症（overactive bladder,OAB）定义为无感染及明显病理改变前提下,出现尿急,伴或不伴有急迫性尿失禁,通常有尿频和夜尿。治疗首选M受体阻滞剂,新上市的M3受体阻滞剂索利那新为目前热门药物。但目前报道多以服用索利那新8周或12周为研究期限。最近国外有报道患者服用索利那新4周,OAB痊愈。本研究对20例服用索利那新4周的OAB患者进行了服药前后分析,了解短期服药对OAB治疗的效果。
作者 陈燕 李金升 孟庆军 王瑞 乔保平 魏金星 文建国
机构地区 郑州大学第一附属医院泌尿外科尿动力学中心
出处 《第三军医大学学报》 CAS CSCD 北大核心 2011年第1期104-105,共2页 Journal of Third Military Medical University
基金 河南省医学科技攻关计划(200801002) 郑州市技术研究与开发经费支持项目(074SGHH32262)
关键词 索利那新 膀胱过度活动 治疗
分类号 R694.053 [医药卫生—泌尿科学]
  • 相关文献

参考文献5

  • 1Abrams P, Swift S. Solifenacin is effective for the treatment of OAB dry patients: a pooled analysis[J]. Eur Urol, 2005, 48(3) : 483 -487.
  • 2吴士良,肖云翔,段继宏,丁强,孙颖浩,黄翼然,宋波,蔡松良,那彦群.索利那新治疗尿急及急迫性尿失禁的有效性和安全性分析[J].中华泌尿外科杂志,2009,30(9):630-634. 被引量：71
  • 3Abrams P, Andersson K E. Muscarinic receptor antagonists for overactive bladder[J]. BJU Int,2007, 100(5) : 987 -1006.
  • 4Debruyne F M, Heesakkers J P. Clinical and socioeconomic relevance of overactive bladder[J]. Urology, 2004, 63(3 Suppl 1 ) : 42 -44.
  • 5Vardy M D, Miteheson H D, Samuels T A, et al. Effects of solifenacin on overactive bladder symptoms, symptom bother and other patient-reported outcomes: results from VIBRANT-a double-blind, placebo-controlled trial[J]. Int J Clin Pract, 2009, 63(12) : 1702 -1714.

二级参考文献16

  • 1Abrams P, Cardozo L, Fall M, et al. The standardisation of terminology of lower urinary tract function, report from the standardisaton subcommittee of the International Continence Society. Neurourol Urodyn, 2002, 21: 167-178.
  • 2Rovner ES, Wein AJ. Incidence and prevalence of overactive bladder. Curr Urol Rep, 2002, 3:434- 438.
  • 3Irwin DE, Milsom I, Kopp Z, et al. Impact of overactive bladder symptoms on employment, social interactions and emotional well-being in six European countries. BJU Int, 2006, 97: 96-100.
  • 4Abrams P, Andersson KE. Muscarinic receptor antagonists for overactive bladder. BJU Int, 2007, 100: 987-1006.
  • 5Ikeda K, Kobayashi S, Suzuki M, et al. M3 receptor antagonism by the novel antimuscarinic agent solifenacin in the urinary bladder and salivary gland. N-S Arch Pharmacol, 2002, 366: 97-103.
  • 6Ohtake A, Ukai M, Hatanaka T, et al. In vitro and in vivo tissue selectivity profile of solifenacin succinate (YM905) for urinary bladder over salivary gland in rats. Eur J Pharmaeol, 2004, 492:243- 250.
  • 7Kobayashi S, Ikeda K, Miyata K. Comparison of in vitro selectivity profiles of solifenacin succinate (YM905) and current antimuscarinic drugs in bladder and salivary glands: a Ca2+ mobilization study in monkey cells. Life Sci, 2004, 74: 843-853.
  • 8Smulders RA, Krauwinkel WJ, Swart PJ, et al. Pharmacokinetics and safety of solifenacin succinate in healthy young men. J Clin Pharmacol, 2004, 44:1023- 1033.
  • 9Chapple CR, Arano P, Bosch JL, et al. Solifenacin appears effective and well tolerated in patients with symptomatic idiopathic detrusor overactivity in a placebo- and tolterodine-controlled phase 2 dose-finding study. BJU Int, 2004, 93: 71-77.
  • 10宋波,杨勇,廖利民.膀胱过度活动症诊断治疗指南∥那彦群.中国泌尿外科疾病诊断治疗指南.北京:人民卫生出版社,2007:330.

共引文献70

同被引文献81

  • 1李斌,李波涌,文定军,唐秀英,张国富.上尿路手术后内置双J管致发热分析[J].中国现代医学杂志,2005,15(3):408-409. 被引量：7
  • 2李外,古今,刘萍.琥珀酸索非那新投放美国市场用于膀胱过度活动症[J].国外医学（药学分册）,2005,32(3):214-215. 被引量：5
  • 3钟大放.以加权最小二乘法建立生物分析标准曲线的若干问题[J].药物分析杂志,1996,16(5):343-346. 被引量：580
  • 4Mealy N, Castaner J. YM-905 [J]. Drugs Future, 1999, 24(8): 871-874.
  • 5Naito R, Yonetoku Y, Okamoto Y, et al. Synthesis and antimuscarinic properties of quinuclidin-3-yl 1,2,3,4-tetrahydroisoquinoline-2-carboxylate derivatives as novel muscarinic receptor antagonists [J]. J Med Chem, 2005, 48 (21) : 6597-6606.
  • 6Wang S, Onaran MB, Seto CT, et al. Enantioselective synthesis of 1-aryltetrahydroisoquinolines [J]. Org Lett, 2010, 12 (12) : 2690-2693.
  • 7Ishii Y, Takaoka K, Inakoshi M, et al. Composition containing solifenacin succinate: EP, 1714965 [P]. 2006-10-25. (CA 2005, 143: 212051).
  • 8Sniegoski LT, Byrd GD, White E. Synthesis of 3-quinuclidinol-18 O, benzilic-d5 acid, and 3-quinuclidinyl- 180 benzilate-d5 [J]. J Labelled Compd Radiopharm, 1989, 27 (9) : 983-993.
  • 9Langlois M, Meyer C, Soulier JL. Synthesis of (R) and (S) - 3-aminoquinuclidine from 3-quinuclidinone and (S) and (R)-l-phenethylamine [J]. Synth Commun, 1992, 22(13): 1895-1911.
  • 10Han XY, Liu H, Liu CH, et al. Synthesis of the optical isomers of a new anticholinergic drug, penehyclidine hydrochloride (8018) [J]. Bioorg Med Chem Lett, 2005, 15(8) : 1979-1982.

引证文献12

二级引证文献18

第三军医大学学报
2011年 第1期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部